申请人:Daewoong Pharmaceutical Co., Ltd.
公开号:US10227338B2
公开(公告)日:2019-03-12
The invention relates to a compound represented by Chemical Formula 1, below, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound or salt. The compound of the invention or pharmaceutically acceptable salts thereof can be used for the prevention or treatment of sodium channel blocker-related diseases.
in Chemical Formula 1,
R1 is hydrogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, halogen, or cyano,
R2 and R3 are each independently hydrogen, or halogen,
R4 is C5-10 heteroaryl containing one or two elements each independently selected from the group consisting of N, S and O, wherein the C5-10 heteroaryl is unsubstituted or substituted with C1-4 alkyl or halogen,
R5 is —CH2CH2—N(R7)(R8), or —CH2CH2CH2—N(R7)(R8), R6 is hydrogen, or C1-4 alkyl; or R5 and R6 together form C3-5 alkylene, (C2-4 alkylene)-N(R9)—(C2-4 alkylene), or (C2-4 alkylene)-O—(C2-4 alkylene), wherein the C3-5 alkylene, or C2-4 alkylene is each independently unsubstituted or substituted with one or two R10,
R7, R8, and R9 are each independently hydrogen, or C1-4 alkyl,
R10 is C1-4 alkyl, C1-4 alkoxy, halogen, amino, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHCO(C1-4 alkyl), or pyrrolidinyl,
X1 is C—R′, or N, wherein R′ is hydrogen, or halogen,
X2 is CH, or N, and
X3 is N—R″, wherein R″ is hydrogen, or C1-4 alkyl.
本发明涉及如下
化学式 1 所代表的化合物、其药学上可接受的盐以及包含该化合物或盐的药物组合物。本发明的化合物或其药学上可接受的盐可用于预防或治疗
钠通道阻滞剂相关疾病。
在
化学式 1 中、
R1 是氢、C1-4 烷基、C1-4 烷氧基、C1-4 卤代烷基、C1-4 卤代烷氧基、卤素或
氰基、
R2 和 R3 各自独立地为氢或卤素、
R4 是 C5-10 杂芳基,含有一个或两个各自独立地选自 N、S 和 O 组成的组的元素,其中 C5-10 杂芳基未被取代或被 C1-4 烷基或卤素取代、
R5 是 -CH2CH2-N(R7)(R8),或 -CH2CH2CH2-N(R7)(R8),R6 是氢或 C1-4 烷基;或 R5 和 R6 共同形成 C3-5 亚烷基、(C2-4 亚烷基)-N(R9)-(C2-4 亚烷基),或 (C2-4 亚烷基)-O-(C2-4 亚烷基),其中 C3-5 亚烷基或 C2-4 亚烷基各自独立地未被取代或被一个或两个 R10 取代、
R7、R8 和 R9 各自独立地为氢或 C1-4 烷基、
R10 是 C1-4 烷基、C1-4 烷氧基、卤素、
氨基、NH(C1-4 烷基)、N(C1-4 烷基)2、NHCO(C1-4 烷基)或
吡咯烷基、
X1 是 C-R′,或 N,其中 R′是氢或卤素、
X2 是 CH 或 N,以及
X3 是 N-R″,其中 R″ 是氢或 C1-4 烷基。